Navigation Links
YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387
Date:12/6/2010

) meeting in December 2010. Nimotuzumab is a humanized monoclonal antibody targeting EGFR with an enhanced side effect profile. Nimotuzumab is being evaluated in numerous Phase II and III trials worldwide by YM's licensees. CYT997 is an orally-available small molecule therapeutic with dual mechanisms of vascular disruption and cytotoxicity, and is currently in a Phase II trial for glioblastoma multiforme. In addition to YM's three clinical stage products, the Company has a library of more than 4,000 novel compounds identified through internal research conducted at YM BioSciences Australia which are currently being evaluated.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process or the ability to obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or to meet commercial demand; and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that our JAK1/JAK2 inhibitor CYT387 and our VDA small molecule CYT997 will generate positive efficacy and safety data in future clinical trials; that YM and its v
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387
2. Ardea Biosciences to Present at Two Upcoming Investor Conferences
3. YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results
4. YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS
5. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
6. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
7. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
8. X-BODY BioSciences Awarded Grant for Therapeutic Discovery Project Targeting Metastatic Tumor Stem Cells
9. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
10. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
11. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500â„¢
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... and SAN JOSE, California , January 15, ... developing antibody-drug conjugates for cancer, today announced the appointment of ... Dr Reynolds has over 20 years, development experience gained in ... Seattle Genetics. "I am delighted to welcome Tom ...
(Date:1/15/2014)... 15, 2014 Two champions of science, ... sponsorship of an annual competition for middle and high ... to, innovative STEM study. The competition presents students with ... of Engineering Aptitude, Mathematics, and Sciences is a ...
(Date:1/15/2014)... January 15, 2014 AudioNotch is the ... therapy for the treatment of tinnitus. Patients listen to ... and over a period of weeks to months, their tinnitus ... in two forms: Notched Music and Notched White Noise. Now, ...
(Date:1/14/2014)... Communications, a leading provider of strategic communications services to corporations and ... the United States and Europe ... JD, is returning to the firm,s Washington, D.C. ... more than two years of service as Associate Commissioner for the ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Former FDA Associate Commissioner Returns To 3D Communications 2
... Netherlands, May 14 Nucletron, a,knowledge-based leader ... release,of Oncentra(R) Brachy, a comprehensive film- and ... planning for brachytherapy.,Oncentra Brachy, the world,s first ... Windows-based planning system that features,state-of-the-art optimization algorithms ...
... 14 Experts from PAREXEL Consulting will present insights ... to be held May 18-21, 2009 at the Georgia ... a business unit of PAREXEL International (Nasdaq: ... and medical device industries. PAREXEL Consulting experts will be ...
... Pharmaxis (ASX: PXS;,Nasdaq: PXSL ) today announced ... Drug Administration (FDA) that the New Drug Application (NDA),for ... for,standard review. The FDA will advise the result ... Pharmaxis is seeking approval for Aridol for ...
Cached Biology Technology:Nucletron Releases Comprehensive Film-and Volume-Based Planning System for Wide Variety of Brachy Solutions 2PAREXEL Consulting Experts To Present Insights Into Achieving Regulatory Approval at the 2009 BIO International Convention 2PAREXEL Consulting Experts To Present Insights Into Achieving Regulatory Approval at the 2009 BIO International Convention 3PAREXEL Consulting Experts To Present Insights Into Achieving Regulatory Approval at the 2009 BIO International Convention 4U.S. FDA Accepts Aridol(TM) New Drug Application for Review 2
(Date:4/23/2014)... This news release is available in French and ... woman? Male or female? In humans and other mammals, the difference ... Y chromosome. It is present only in males, where the two ... chromosomes. Thus, the Y is ultimately responsible for all the morphological ... not always been the case. A very long time ago, the ...
(Date:4/23/2014)... People diagnosed with Huntington,s disease, most in their ... mental, physical, and behavioral decline within two decades. ... of the genetic disease, have been the primary ... But according to new research from Prof. Gerardo ... University,s Department of Cell Research and Immunology, in ...
(Date:4/23/2014)... Valley, NY. (Apr. 23 2014) A ... neural stem cells (hNSCs) into the brains of ... after 22 and 24 months found that the ... and did not cause tumors. , The study ... Cell Transplantation but is currently freely ...
Breaking Biology News(10 mins):Male or female? 2Male or female? 3On the defensive 2On the defensive 3Study finds long-term survival of human neural stem cells transplanted into primate brain 2
... Chironex species are among the most venomous animals in ... venom, though, which kills by rapidly punching holes in human ... according to research published December 12 in the open access ... University of Hawaii and colleagues. The researchers ...
... be some in that cookie? Now you can find out ... A team of researchers from the UCLA Henry Samueli School ... called the iTube, which attaches to a common cell phone ... the cell phone,s built-in camera, along with an accompanying smart-phone ...
... the Great Lakes, including phosphorus-rich Lake Erie, is an age-old ... of scientists, including Mercyhurst University biologist Steven Mauro, Ph.D. ... avian botulism are linked to Cladophora and scientific ... renewed attention in the nuisance algae. For Mauro, whose ...
Cached Biology News:Got food allergies? Thanks to UCLA, you can test your meal on the spot using a cell phone 2Got food allergies? Thanks to UCLA, you can test your meal on the spot using a cell phone 3Grant furthers Mercyhurst research for human pathogens in Great Lakes 2
...
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
... siRNA Custom Synthesis Service provides ... RNA to knockdown any gene. ... RNA base pairs with terminal ... or other lengths of your ...
Alexa Fluor 647 anti-mouse Qa-2...
Biology Products: